Displaying 81 - 100 of 141
KNH Online Inc. (Adderin dietary supplement)
Date
By
Devin Willis fka Devin Domond, Former Chief of Staff for Advertising Practices
File
Text of the Letter
(259.11 KB)
Perfect Prime Anti-Aging Face Serum
Date
By
Devin Willis fka Devin Domond, Former Chief of Staff for Advertising Practices
File
Text of the Letter
(332.13 KB)
Max Synapse LLC and Super Flora Probiotic, LLC (dietary supplements)
Date
By
Devin Willis fka Devin Domond, Former Chief of Staff for Advertising Practices
File
Text of the Letter
(304.65 KB)
Marketer That Deceptively Advertised Bed Bug Treatment Admits Violating FTC Order; Will Be Barred from Bed Bug Product Sales and Pay $224,356 for Consumer Refunds
Date
Chemical Free Solutions LLC (CFS), the seller of Cedarcide Original, a line of cedar oil-based products deceptively marketed as effective at stopping and preventing bed bug infestations, has settled...
FTC, Maine Attorney General Shut Down Web of Deceptive Supplement Sellers
Date
The Federal Trade Commission and the Maine Office of the Attorney General today announced a complaint and three settlements with dietary supplement marketers who allegedly used radio infomercials...
FTC Issues Enforcement Policy Statement Regarding Marketing Claims for Over-the-Counter Homeopathic Drugs
Date
The Federal Trade Commission today announced a new “Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs.” The policy statement was informed by an FTC workshop...
Operators of Phony Doctor Certification Program and Misleading Health and Lifestyle Websites Settle FTC Charges
Date
According to the FTC’s complaint, between June 2013 and October 2015 the defendants marketed and sold the “Doctor Trusted” seal and certification program to websites that primarily offered health...
Marketers of “Mosquito Shield Bands” to Pay $300,000, Barred from Making Misleading Pest-Control Claims under Settlement with FTC
Date
CORRECTED The quote in this release has been updated for clarification. Viatek Consumer Products Group, Inc. and company owner and President Lou Lentine have agreed to settle Federal Trade Commission...
Impax Laboratories Inc./Medicis Pharmaceutical Corp./Sandoz Inc. (Solodyn)
Date
Matter Number
121 0083
File
File
File
Closing Letter To Counsel for Sandoz Inc.
(53.38 KB)
File
Closing Letter To Counsel for Mylan Inc.
(49.05 KB)
FTC Files Amicus Brief Explaining that Pharmaceutical “Product Hopping” Can Violate the Antitrust Laws
Date
The Federal Trade Commission filed an amicus brief before the U.S. Court of Appeals for the Third Circuit explaining that the district court made significant analytical errors in ruling for defendants...
Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.
Date
Citation Number
15-2236
Federal Court
U.S. Circuit Court of Appeals for the Third Circuit
Brief of the Federal Trade Commission urging the Third Circuit to reverse the district court’s summary judgment ruling, which held (1) that a brand-name drug manufacturer lacked monopoly power and (2)...
File
FTC Staff Comment: FDA Should Reevaluate Its Current Regulatory Framework for Homeopathic Products
Date
The staff of the Federal Trade Commission has recommended that the U.S. Food and Drug Administration reconsider the framework it uses to regulate homeopathic medications because it may appear to...
FTC, Florida Attorney General Sue to Stop Deceptive Robocalls from Operation That Pitched Seniors “Free” Medical Alert Systems
Date
The Federal Trade Commission has filed a joint complaint with the Florida Attorney General’s Office charging a New York-based operation known as Lifewatch with using blatantly illegal and deceptive...
FTC to Host September Workshop in Washington, DC, to Examine Advertising for Over-the-Counter Homeopathic Products
Date
FTC invites public to submit research, discussion topics, and requests to participate as panelists.
FTC Returns $3 Million to Consumers in Cactus Juice Scam
Date
The Federal Trade Commission is mailing almost 500,000 checks totaling approximately $3 million to consumers who lost money to diet supplement marketers who made unsupported claims that their cactus...
PhRMA a/k/a Pharmaceutical Research and Manufacturers of America
Type of Action
Federal
Last Updated
FTC Matter/File Number
P072104
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
141 0159
Displaying 81 - 100 of 141